Cannabix Technologies (OTCMKTS:BLOZF) shares rose 13.88% on Thursday to $0.568 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.10 to $0.81.
In a press release, Cannabix Technologies provided a development update on its FAIMS Beta 2.0 or marijuana breathalyzer for the detection of 9-tetrahydrocannabinol in human breath. Its development in Florida and Vancouver is going well and the company expects to begin pre-trial live subject testing during the month of March.
Over the last three months, the company made various technical leaps with several components. “In particular, the dielectric barrier discharge ionization source (“DBD”) which allows efficient ionization with relatively low voltages, has been significantly optimized in every aspect of the source (sizes, geometries, and materials) leading to significantly smaller instrument footprint. In addition, the high-voltage square wave generator (“HVSW”) which causes ions to oscillate rapidly at a high frequency between the FAIMS electrodes, to create separation from each other, has been drastically improved,” the press release indicated.
Aside from that, Cannabix Technologies is working with its Vancouver based engineering firm to ruggedize and refine its breath collection component. Engineers are testing a proprietary flow-through heat exchanger technology that stabilizes breath temperature in extreme cold as well as humid temperature settings.
Last December, a special Task Force set up by the Government of Canada to review the future regulation of recreational cannabis in Canada issued a report that emphasized the role of marijuana in impaired driving. The report recommended supporting the development of an appropriate roadside drug screening device for detecting THC levels and investing in baseline data collection and ongoing surveillance and evaluation in collaboration with provinces and territories.
Note that Canada is expected to table marijuana legalization legislation in the spring so Cannabix Technologies is ramping up its efforts to get the breathalyzer ready and use key metrics and guidance from Drugs and Driving Committee to establish testing parameters for drug-impaired driving.
Cannabix Technologies is a leader in marijuana breathalyzer development for law enforcement and the workplace. It has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions.
The company is working to develop drug-testing devices that will detect THC, which is the psychoactive component of marijuana that causes intoxication, using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.